PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > Guidelines : Osteoporosis

Guidelines : Osteoporosis

Additional Documents

Other Drugs

Committee Recommendations

Date
Committee Name
Narrative
06 November 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee have agreed an High Cost drug Osteoporosis pathway as a temporary measure until the entire Algorithm 1 is reviewed.

Abaloparatide has been added to the algorithm following the publication of NICE TA991.

Please note that algorithm 1 in the Osteoporosis Guidelines has not been updated

03 August 2022
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee have agreed an updated Osteoporosis Treatment Pathway - Algorithm 1.

Romosozumab has been added to the algorithm following the publication of NICE TA791 in May 2022. 

Please note that algorithm 1 in the Osteoporosis Guidelines has not been updated

02 June 2021
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Osteoporosis guidelines have been reviewed and updated.

The guidelines are supported by two algorithms which have been extracted from the guideline and provided as separate documents (below) for ease of use:
Algorithm 1 - Treatment Pathway for adults
Algorithm 2 - Review of Long-term Bisphosphonate Therapy 

Calcium & vitamin D:
AdcalD3/ AccreteD3 twice daily formulations are the preferred calcium and vitamin D supplements.
Accrete D3 One a Day, Calci-D chewable tablets or theiCal-D3 chewable tablets are once daily options for patients with compliance issues.
 

This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More